Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Spinal Cord Neoplasms 1Pinealoma 1Lymphoma, Follicular 1Glioma 1Glioblastoma 1Choroid Plexus Carcinoma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 94Radiotherapy 40Bevacizumab 40Lomustine 21Radiation 18Surgical Procedures, Operative 10Carboplatin 9pembrolizumab 8Nivolumab 8Carmustine 8Irinotecan 7IL13-PE38 6Granulocyte-Macrophage Colony-Stimulating Factor 6Flucytosine 6Cyclophosphamide 6ABT-414 6vocimagene amiretrorepvec 5depatuxizumab mafodotin 5Valacyclovir 5Drug Therapy 5veledimex 4sargramostim 4enzastaurin 4NVP-BKM120 4Gemcitabine 4Dianhydrogalactitol 4Chlorotoxin 4Aminolevulinic Acid 4verubulin 3selinexor 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Glioblastoma × perillyl alcohol × Clear all
NCT02704858 2026-03-02

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

Neonc Technologies, Inc.

Phase 1/2 Recruiting
49 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡